Dyne Therapeutics, Inc. (NASDAQ:DYN)
| Market Cap | 2.98B+14.5% |
| Revenue (ttm) | n/a |
| Net Income | n/a |
| EPS | n/a |
| Shares Out | 186.75M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | n/a |
| Day's Range | n/a |
| 52-Week Range | n/a |
| Beta | 1.12 |
| Analysts | n/a |
| Price Target | 36.88(+130.93%) |
| Earnings Date | n/a |
Dyne Therapeutics, Inc. has a live Insider Score.
Scored on 1 qualifying trade from 1 insider in the last 90 days.
About DYN
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$DYN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in DYN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by DYN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
DYN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
DYN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Personnel related | $28.79M | 43.47% |
| Stock-based compensation | $14.98M | 22.61% |
| Facility-related and other | $12.50M | 18.87% |
| Professional and consulting fees | $9.97M | 15.06% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New DYN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to DYN from public contracts
Source: USAspending.gov
DYN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from DYN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score